Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.42 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.42 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.42 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.42 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17191865 | 0.77 | PTGDR2 (0.38) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL21527809 | 0.72 | CA2 (0.46) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL17097221 | 0.70 | CA9 (0.58) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL22226932 | 0.70 | CA9 (0.58) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL13534170 | 0.70 | CA9 (0.58) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL13534186 | 0.70 | CA9 (0.58) | CA9CA2ABCC9ABCC8KCNJ11 | |
| SCHEMBL15680415 | 0.70 | EIF2AK2 (0.32) | CA9CA2EIF2AK2PKLRL3MBTL1 | |
| SCHEMBL107126 | 0.68 | CA9 (1.00) | CA9CA2HSD11B1CA12CYP2C19 | |
| SCHEMBL17193079 | 0.68 | APP (0.48) | L3MBTL1KDM4EBCL2MCL1 | |
| SCHEMBL8547101 | 0.67 | CA9 (0.53) | CA9CA2ABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | FEDORA PHARMACEUTICALS INC. (CA) | 2023-10-10 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | CA9 496/4885CA2 521/4885ABCC9 291/4885 |
| US-11780832-B2 | Lactivicin compounds, their preparation and use as antibacterial agents | LCT, VIP, LPO | CA9 1522/4885CA2 3313/4885ABCC9 2709/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | CA9 194/4885CA2 42/4885ABCC9 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.